- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Update on Migraine Patient Care Challenges During the Pandemic
Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.
Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with Deena E. Kuruvilla, MD, FAHS, the medical director of the Westport Headache Institute. She and Matt Hoffman, managing editor of NeurologyLive®, another MJH Life Sciences™ medical news website, had a conversation a few weeks after this year’s American Headache Society Annual Scientific Meeting.
They discuss the obstacles patients with migraine face during the pandemic to getting necessary care, the effect of worsening lifestyle changes over the past year and a half on patients with headaches, the difficulty in finding a clinician who knows about the latest migraine treatments, issues related to prior authorization, and more.
Watch the full interview on Medical World News®, and read more about migraine here.
Listen above or through one of these podcast services:
The Impact of Nurse Practitioner Attribution in Medicare Shared Savings ACOs
December 5th 2023Allowing nurse practitioners to serve as attribution-eligible providers for Medicare Shared Savings Program accountable care organizations leads to no change in hierarchical condition category risk scores and modest growth in attributed beneficiaries.
Read More
Imetelstat Offers Benefits for Patients With MDS Who Are Red Blood Cell–Transfusion Dependent
December 5th 2023The past year has offered new hope for patients with lower-risk myelodysplastic syndromes. Besides imetelstat, which has an FDA deadline for action of June 2024, the agency approved luspatercept, which has a different mechanism of action.
Read More
